Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu‑PSMA‑617 radioligand‑therapy in prostate cancer

• Ovidio Fernández Calvo ^[1] ; José Muñoz Iglesias ^[4] ; Estephany Abou Jokh Casas ^[2] ; Aura Molina Díaz ^[5] ; Urbano Anido Herranz ^[3] ; Javier Casas Nebra ^[6] ; Lucía García Bernardo ^[3] ; Sara Martínez Breijo ^[7] ; Martín Lázaro Quintela ^[8] ; Gloria Muñiz García ^[1] ; Sergio Vázquez Estevez ^[9]
  1. [1] Complexo Hospitalario Universitario de Ourense

     Complexo Hospitalario Universitario de Ourense

     Ourense, España

     
  2. [2] Hospital Universitario Lucus Augusti

     Hospital Universitario Lucus Augusti

     Lugo, España

     
  3. [3] Complexo Hospitalario Universitario de Santiago

     Complexo Hospitalario Universitario de Santiago

     Santiago de Compostela, España

     
  4. [4] Department of Nuclear Medicine (SERGAS), University Hospital of Vigo, Meixoeiro Hospital, Vigo, Spain
  5. [5] Department of Medical Oncology, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain
  6. [6] Uro-Oncology Unit, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain
  7. [7] Department of Urology, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain
  8. [8] Department of Medical Oncology, University Hospital of Vigo, Meixoeiro Hospital, Vigo, Spain
  9. [9] Department of Medical Oncology, Hospital Universitario Lucus Augusti de Lugo, Lugo, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 4, 2025, págs. 1383-1397
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Theragnostic is a type of precision medicine that uses molecules linked to radioactive isotopes for the diagnosis and treatment of diseases. In recent years, it has gained signifcant importance to treat neuroendocrine tumors and is currently being used in prostate cancer. Various radiopharmaceuticals have emerged for diagnosing and detecting lesions showing prostatespecifc membrane antigen (PSMA) positivity on the Positron emission tomography/computed tomography scan, being the most widely used labeled with [ 68Ga] and [ 18F]. Its use as therapy in prostate cancer (PC) has been assessed in the VISION, TheraP, and PSMAfore clinical trials conducted with the radioligand [ 177Lu]Lu-PSMA-617, demonstrating signifcant antitumor activity. The aim of this article is to present practical recommendations, based on current available scientifc evidence and on a multidisciplinary consensus, for the diagnosis and treatment with [ 177Lu]Lu-PSMA-617 in patients with PC.